Teleflex (NYSE:TFX) won FDA clearance for expanded sizes and uses of its Arrow GPSCath Balloon Dilatation catheter, a device the company picked up during the 2012 buyout of Hotspur Technologies.
The FDA win lets Teleflex sell the catheter in new 80 cm lengths and in a higher burst pressure rating. The Limerick, Pa.-based device company calls the Arrow GPS a "dual-function" balloon catheter because of its ability to widen arteries while injecting fluids.
"There are approximately 20 million patients with peripheral vascular disease who could benefit from this multi-purpose approach to catheter design, and we are excited to bring this innovative peripheral access product to market," said CEO Benson Smith in prepared remarks.
Last month, Teleflex bought out late-stage device company Eon Medical for its scar-reducing microlaparoscopy platform and landed European clearance for its Arrow GPSCath Balloon Dilation Catheter.